BioCentury
ARTICLE | Clinical News

Vantictumab: Interim Ph Ib data

November 17, 2016 10:47 PM UTC

Interim data from 21 evaluable patients in an open-label, dose-escalation, U.S. Phase Ib trial showed that IV vantictumab on days 1 and 15 of each 28-day cycle plus Abraxane nab-paclitaxel and gemcitabine led to an ORR of 48%, including 10 partial responses, plus 8 cases of stable disease. The combination was well tolerated with fatigue, nausea and dysgeusia reported as the most common vantictumab-related toxicities. Progression-free survival (PFS) and overall survival (OS) data are not yet mature and the MTD has not yet been reached. Data were presented at the European Society for Medical Oncology meeting in Copenhagen...

BCIQ Company Profiles

OncoMed Pharmaceuticals Inc.

BCIQ Target Profiles

Frizzled homolog 7 (FZD7)